354 related articles for article (PubMed ID: 28623912)
21. Potential Role of microRNAs in inducing Drug Resistance in Patients with Multiple Myeloma.
Allegra A; Ettari R; Innao V; Bitto A
Cells; 2021 Feb; 10(2):. PubMed ID: 33672466
[TBL] [Abstract][Full Text] [Related]
22. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms.
Mora Y; Reyes ME; Zanella L; Mora B; Buchegger K; Ili C; Brebi P
Pharmacogenomics; 2021 Aug; 22(12):777-790. PubMed ID: 34281355
[TBL] [Abstract][Full Text] [Related]
23. Epigenetics in multiple myeloma: From mechanisms to therapy.
Alzrigat M; Párraga AA; Jernberg-Wiklund H
Semin Cancer Biol; 2018 Aug; 51():101-115. PubMed ID: 28962927
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
25. PRC2 targeting is a therapeutic strategy for EZ score defined high-risk multiple myeloma patients and overcome resistance to IMiDs.
Herviou L; Kassambara A; Boireau S; Robert N; Requirand G; Müller-Tidow C; Vincent L; Seckinger A; Goldschmidt H; Cartron G; Hose D; Cavalli G; Moreaux J
Clin Epigenetics; 2018 Oct; 10(1):121. PubMed ID: 30285865
[TBL] [Abstract][Full Text] [Related]
26. New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
Cea M; Cagnetta A; Gobbi M; Patrone F; Richardson PG; Hideshima T; Anderson KC
Curr Pharm Des; 2013; 19(4):734-44. PubMed ID: 23016853
[TBL] [Abstract][Full Text] [Related]
27. Melanoma epigenetics: novel mechanisms, markers, and medicines.
Lee JJ; Murphy GF; Lian CG
Lab Invest; 2014 Aug; 94(8):822-38. PubMed ID: 24978641
[TBL] [Abstract][Full Text] [Related]
28. Regulation of microRNAs by epigenetics and their interplay involved in cancer.
Liu X; Chen X; Yu X; Tao Y; Bode AM; Dong Z; Cao Y
J Exp Clin Cancer Res; 2013 Nov; 32(1):96. PubMed ID: 24261995
[TBL] [Abstract][Full Text] [Related]
29. DNA methylation of microRNA genes in multiple myeloma.
Wong KY; Huang X; Chim CS
Carcinogenesis; 2012 Sep; 33(9):1629-38. PubMed ID: 22715154
[TBL] [Abstract][Full Text] [Related]
30. An overview of epigenetic agents and natural nutrition products targeting DNA methyltransferase, histone deacetylases and microRNAs.
Huang D; Cui L; Ahmed S; Zainab F; Wu Q; Wang X; Yuan Z
Food Chem Toxicol; 2019 Jan; 123():574-594. PubMed ID: 30408543
[TBL] [Abstract][Full Text] [Related]
31. Epigenetic Targets and their Inhibitors in Cancer Therapy.
Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
[TBL] [Abstract][Full Text] [Related]
32. A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma.
Nylund P; Atienza Párraga A; Haglöf J; De Bruyne E; Menu E; Garrido-Zabala B; Ma A; Jin J; Öberg F; Vanderkerken K; Kalushkova A; Jernberg-Wiklund H
Cell Death Dis; 2021 Feb; 12(2):167. PubMed ID: 33579905
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors potentiate photodynamic therapy in colon cancer cells marked by chromatin-mediated epigenetic regulation of
Halaburková A; Jendželovský R; Kovaľ J; Herceg Z; Fedoročko P; Ghantous A
Clin Epigenetics; 2017; 9():62. PubMed ID: 28603560
[TBL] [Abstract][Full Text] [Related]
34. Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.
Rastgoo N; Pourabdollah M; Abdi J; Reece D; Chang H
Leukemia; 2018 Nov; 32(11):2471-2482. PubMed ID: 29743723
[TBL] [Abstract][Full Text] [Related]
35. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
36. Diabetic nephropathy: The regulatory interplay between epigenetics and microRNAs.
Sankrityayan H; Kulkarni YA; Gaikwad AB
Pharmacol Res; 2019 Mar; 141():574-585. PubMed ID: 30695734
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
Lu Y; Chan YT; Tan HY; Li S; Wang N; Feng Y
Mol Cancer; 2020 Apr; 19(1):79. PubMed ID: 32340605
[TBL] [Abstract][Full Text] [Related]
38. The Development of Epigenetics and Related Inhibitors for Targeted Drug Design in Cancer Therapy.
Liu N; Zhao R; Ma Y; Wang D; Yan C; Zhou D; Yin F; Li Z
Curr Top Med Chem; 2018; 18(28):2380-2394. PubMed ID: 30430946
[TBL] [Abstract][Full Text] [Related]
39. Roles of noncoding RNAs in drug resistance in multiple myeloma.
Li J; Zou J; Wan X; Sun C; Chu Z; Hu Y
J Cell Physiol; 2020 Nov; 235(11):7681-7695. PubMed ID: 32324301
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic silencing of miR-335 induces migration by targeting insulin-like growth factor-1 receptor in multiple myeloma.
Qi J; Shi LY; Wu Y; Shen XJ; Yuan J; Jin CJ; Cong H; Ju SQ
Leuk Lymphoma; 2019 Dec; 60(13):3188-3198. PubMed ID: 31190579
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
